Managing Director, Mid Atlantic Region, Danforth Advisors

Danforth’s services range from day-to-day finance and accounting functions to strategic CFO advisory, financial planning and analysis, and transactional support/execution for public offerings and M&A, solely for life science companies 

Board of Directors and Audit Committee Chairman of Emmaus Life Sciences

Rob is experienced in all stages of the corporate lifecycle, including start-up operations, high growth, turnarounds and exit strategies

Expertise includes public and private financings, M&A, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as interactions with boards, venture capitalists, shareholders and Wall Street

Prior to joining Danforth, Rob served as CFO to multiple companies, including Motif Bio (NASDAQ/AIM: MTFB), Tyme Technologies, Inc. (NASDAQ: TYME), BeyondSpring Pharmaceuticals, Inc., and NeoStem, Inc. – now Caladrius Biosciences, Inc. (NASDAQ: CLBS)

He previously spent nearly 20 years in investment banking at Lehman Brothers and Legg Mason